Ações Caris Life Sciences, Inc. (CAI) — é um bom negócio?

Ações Caris Life Sciences, Inc. (CAI) — é um bom negócio? — InspectStocks

Como ganha dinheiro

Molecular profiling services97%
Pharma research and development services4%

As participações na receita são estimativas para six months ended June 30, 2026, não números de um relatório oficial.

Concorre com

RHHBYFoundation Medicine (a Roche subsidiary)
TEMTempus AI
C
Tamanho
US$ 13,1B
Margem
-12,5%
GHGuardant Health
B
Tamanho
US$ 20,5B
Margem
-37,9%
NTRANatera
B
Tamanho
US$ 46,3B
Margem
-5,7%
GRALGRAIL
D
Tamanho
US$ 5,2B
Margem
-243,8%
PSNLPersonalis
D
Tamanho
US$ 1,7B
Margem
-147,7%

O que vende6

MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.

Mostrar mais 3

Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.

Quem compra4

Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
Government and commercial health insurers pay for some patient tests when they cover the test and its use.
Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
Academic cancer centers and researchers use Caris data and collaborate on cancer research.

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.

O que pode dar errado

1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.

Demonstrações financeiras completas →

Sobre a Caris Life Sciences, Inc.

Caris analyzes DNA and RNA from cancer tissue and blood to find molecular features that may help doctors choose treatments. Its tests examine the whole exome—the protein-coding parts of DNA—or the whole transcriptome, and the company uses artificial intelligence (AI) and machine learning (ML) to interpret results. Caris also provides data and research services to drug companies and uses patient samples and data to investigate potential cancer drug targets.

Sede: Irving, Texas
Fundada em: 2008
Listada em: Nasdaq
Fim do exercício: December 31

Construído a partir dos próprios documentos de Caris Life Sciences, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.

Keep exploring

The themes Caris Life Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Como ganha dinheiro

Molecular profiling services97%
Pharma research and development services4%

As participações na receita são estimativas para six months ended June 30, 2026, não números de um relatório oficial.

Concorre com

RHHBYFoundation Medicine (a Roche subsidiary)
TEMTempus AI
C
Tamanho
US$ 13,1B
Margem
-12,5%
GHGuardant Health
B
Tamanho
US$ 20,5B
Margem
-37,9%
NTRANatera
B
Tamanho
US$ 46,3B
Margem
-5,7%
GRALGRAIL
D
Tamanho
US$ 5,2B
Margem
-243,8%
PSNLPersonalis
D
Tamanho
US$ 1,7B
Margem
-147,7%

O que vende6

MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.

Mostrar mais 3

Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.

Quem compra4

Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
Government and commercial health insurers pay for some patient tests when they cover the test and its use.
Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
Academic cancer centers and researchers use Caris data and collaborate on cancer research.

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.

O que pode dar errado

1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.

Demonstrações financeiras completas →

Sobre a Caris Life Sciences, Inc.

Sede: Irving, Texas
Fundada em: 2008
Listada em: Nasdaq
Fim do exercício: December 31

Como ganha dinheiro

Concorre com

O que vende6

Quem compra4

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

O que pode dar errado

Sobre a Caris Life Sciences, Inc.

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Como ganha dinheiro

Concorre com

O que vende6

Quem compra4

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

O que pode dar errado

Sobre a Caris Life Sciences, Inc.

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Caris Life Sciences, Inc.

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Crescimento e caixa — 5 de 5

Tendência do negócio

Preço da ação e nota ao longo do tempo

Como ganha dinheiro

Concorre com

O que vende6

Quem compra4

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

O que pode dar errado

Sobre a Caris Life Sciences, Inc.

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Como ganha dinheiro

Concorre com

O que vende6

Quem compra4

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

O que pode dar errado

Sobre a Caris Life Sciences, Inc.

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Caris Life Sciences, Inc.

Desempenho passado

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Crescimento e caixa — 5 de 5

Tendência do negócio

Preço da ação e nota ao longo do tempo